Diagnostic yield of screening for SARS-CoV-2 among patients admitted to hospital for alternate diagnoses: an observational cohort study

Objectives To determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19 and to identify risk factors for positive tests.Design Cohort from the Canadian COVID-19 Emergency Department Rapid Response Network registry.Setting 30 acute ca...

Full description

Bibliographic Details
Main Authors: Eddy Lang, Jeffrey P Hau, Corinne M Hohl, Raoul Daoust, Ivy Cheng, Andrew D McRae, Philip Davis, Rhonda Rosychuk, Joel Turner, Jaspreet Khangura, Maja Stachura, Patrick T Fok, Baljeet Brar
Format: Article
Language:English
Published: BMJ Publishing Group 2022-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/8/e057852.full
Description
Summary:Objectives To determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19 and to identify risk factors for positive tests.Design Cohort from the Canadian COVID-19 Emergency Department Rapid Response Network registry.Setting 30 acute care hospitals across Canada.Participants Patients hospitalised for non-COVID-19-related diagnoses who were tested for SARS-CoV-2 between 1 March and 29 December 2020.Main outcome Positive nucleic acid amplification test for SARS-CoV-2.Outcome measure Diagnostic yield.Results We enrolled 15 690 consecutive eligible adults who were admitted to hospital without clinically suspected COVID-19. Among these patients, 122 tested positive for COVID-19, resulting in a diagnostic yield of 0.8% (95% CI 0.64% to 0.92%). Factors associated with a positive test included presence of fever, being a healthcare worker, having a positive household contact or institutional exposure, and living in an area with higher 7-day average incident COVID-19 cases.Conclusions Universal screening of hospitalised patients for COVID-19 across two pandemic waves had a low diagnostic yield and should be informed by individual-level risk assessment in addition to regional COVID-19 prevalence.Trial registration number NCT04702945.
ISSN:2044-6055